Peregrine Capital Management’s Azenta AZTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-144,905
Closed -$3.06M – 291
2026
Q1
$3.06M Sell
144,905
-6,115
-4% -$183K 0.11% 239
2025
Q4
$5.02M Sell
151,020
-2,056
-1% -$67.2K 0.15% 200
2025
Q3
$4.4M Sell
153,076
-4,050
-3% -$126K 0.13% 229
2025
Q2
$4.84M Buy
157,126
+2,656
+2% +$74.7K 0.15% 213
2025
Q1
$5.35M Buy
154,470
+5,093
+3% +$234K 0.18% 178
2024
Q4
$7.47M Buy
149,377
+52,120
+54% +$2.37M 0.22% 124
2024
Q3
$4.71M Buy
97,257
+214
+0.2% +$11.1K 0.14% 226
2024
Q2
$5.11M Buy
97,043
+1,259
+1% +$67.3K 0.15% 227
2024
Q1
$5.77M Buy
95,784
+31
+0% +$1.99K 0.17% 212
2023
Q4
$6.24M Sell
95,753
-16,556
-15% -$898K 0.19% 200
2023
Q3
$5.64M Sell
112,309
-7,087
-6% -$356K 0.17% 225
2023
Q2
$5.57M Sell
119,396
-43
-0% -$1.88K 0.15% 235
2023
Q1
$5.33M Buy
119,439
+3,538
+3% +$175K 0.15% 238
2022
Q4
$6.75M Sell
115,901
-3,521
-3% -$180K 0.21% 217
2022
Q3
$5.12M Sell
119,422
-6,625
-5% -$396K 0.17% 229
2022
Q2
$9.09M Buy
+126,047
New +$9.42M 0.27% 158

Other funds holding AZTA

Peregrine Capital Management's AZTA Position: Q2 2026 in Review

Peregrine Capital Management sold out of Azenta (AZTA) in Q2 2026, closing a stake of 144,905 shares — an estimated $3.06M sold.

Peregrine Capital Management first reported a position in AZTA in Q2 2022 and held it in 16 quarters. The position peaked at $9.09M in Q2 2022. 249 funds tracked by Wall St. Rank hold AZTA as of Q2 2026.

  • Peregrine Capital Management reported no remaining Azenta position as of Q2 2026 after selling out during the quarter.
  • Peregrine Capital Management sold 144,905 Azenta shares in Q2 2026, an estimated $3.06M.
  • Peregrine Capital Management first reported a position in Azenta in Q2 2022 and held it in 16 quarters.
  • Peregrine Capital Management's Azenta position peaked at $9.09M in Q2 2022.
  • 249 funds tracked by Wall St. Rank held Azenta as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.